

### **ACT-Accelerator** – the next 7 days

### WHO MS COVID-19 Briefing

24 September 2020

### 3 key issues upcoming in the next 7 days

- 1. Core ACT-A documents: release target 25 Sept
  - ACT-A Status Report & Plan
  - ACT-A Economic Investment Case
- 2. ACT-A at UNGA: 30 Sept, 8:30-10:00hr (EST)

**3.** Rapid Diagnostics: DG briefer (28 Sept); MS briefing (1 Oct)

### **The ACT-Accelerator Plan & Investment Case**

### for release tomorrow, 25 September




*Status Report & Plan* provides an overview of ACT-Accelerator's goal, approach, achievements to date & near-term priorities.

*Investment Case* provides an economic rationale for investing in ACT-A as a global, integrated, 'end-to-end' solution.




Developed collectively by Partners in consultation with the Facilitation Council

## **ACT-A goal:** accelerated global access to tools that rapidly reduce risk of severe disease & end acute phase of pandemic



### ACT-A's critical path uses accelerated & parallel workstreams to rapidly achieve its goal



### Some key landmarks from the start-up phase

- **Diagnostics**: new Ag RDT (+ EUL)
- Vaccines: COVAX Facility in business (159 countries & growing)
- Allocation: WHO Framework is the emerging standard
- **Therapeutics**: Dexamethasone now in rollout....

Concrete outcomes of the ACT-Accelerator Collaboration

### Immediate priorities for Sept – Dec 2020


	R&D	Manufacturing	<b>Procurement</b>	中 Delivery
<b>Vaccines</b>	Add 1-5 candidates to portfolio based on imminent readouts	Negotiate new deals w based on imminent Ph		Step up country preparedness efforts to deploy as soon as possible
Therapeutics	Evaluate new monoclonal antibodies and antivirals	Select molecules for 1 <sup>st</sup> wave of manufacturing capacity reservations	Launch 3-5 further market interventions for repurposed medicines	Scale up Dexamethasone
Diagnostics	Accelerate evaluation of novel diagnostics		Roll out 10s of millions of antigen-detecting RDTs	Pre-empt deployment needs for antigen- detecting RDTs



Cross-cutting priorities detailed in Plan



# **Financing Requirements & Economic Rationale:** the \$US35 Bn is paid back in 36 hours, once int'l mobility & trade is restored



1. Additional critical funding required by end of 2020 to meet ACT-Acceleator targets (excl. proportion already funded); 2. As of 7 September 2020; 3. Assuming 25% of total ask in 2020

# ACT-A at UNGA: 30 September 2020



#### Accelerating the end of the COVID-19 pandemic: taking new solutions to scale and making them equitably accessible, to save lives, protect health systems and restart the global

economy

Concept: high-level side event on the ACT-Accelerator at the 75th session of UNGA

30 September, 8:30-10:00am EST

#### Objectives

The overarching objectives of this event are to:

- build stronger political consensus for a coordinated global response to COVID-19 and champion the importance and urgency of equitable access to new tools, especially effective vaccines
- catalyze a step-change in support for the Access to COVID-19 Tools Accelerator (ACT-A), and its mechanisms like the COVAX Vaccines Facility, the most promising
  multilateral solutions for global equitable access to the tools needed to accelerate the end of the pandemic

#### Context

The UN has from the outset of the pandemic been calling for global solidarity to combat COVID-19. The already overwhelming burden on health systems, and social and economic consequences, could deteriorate further with subsequent waves of the disease that could prove especially challenging for vulnerable countries and populations.

### **UNGA high-level event on ACT-Accelerator**

- 30<sup>th</sup> September 2020, 08:30-10:00hr (EST)
- Convenor: UN Secretary-General

co-Hosts: UK, South Africa, WHO

#### **Current Programme**

Opening

*High-level statements:* human & economic toll; celebrate ACT-A collaboration & success, call for urgent political & financial support

Saving lives, protecting health systems & restarting global economy with new & existing tools Statements: Heads of State/Gov't, World Bank, UNAIDS, CSO

Economic, moral & political imperatives for a global, integrated end-to-end solution; roll out of new tests & treatments

**Bringing a global solution to life**: realizing full promise of ACT-A & its COVAX Facility

*Statements and Panel*: HoS, Industry rep, GAVI, CEPI, UNICEF Showcase COVAX Facility and commitments


**Closing & way forward** 

High level statements: new commitments, Call to Action

#### Registration opens 12.00EST, tomorrow (25 Sept) at

https://access-for-all.world-television.com/register

### The ACT-A Advocacy Campaign



for ACT-A scale up & impact


### 3 key issues upcoming in the next 7 days

- 1. Core ACT-A documents: release target 25 Sept
  - ACT-A Status Report & Plan
  - ACT-A Economic Investment Case
- 2. ACT-A at UNGA: 30 Sept, 8:30-10:00hr (EST)


**3.** Rapid Diagnostics: DG briefer (28 Sept); MS briefing (1 Oct)

### Back up


### ACT-A is a bold structure, driving unprecedented collaboration



**The economic argument** | unprecedented domestic stimulus has helped hedge the crisis but only in some sectors & countries



# Sectors that depend heavily on international trade & mobility will not recover with existing government stimulus



<sup>1</sup> pre-COVID GDP at end of 2021 expected to be \$US 152 trillion worldwide. In April, forecasts post-COVID predicted \$US 138 trillion. The loss for G20 economies would be ~\$US 10 - 13 trillion, IMF, World Bank; <sup>2</sup> 2020 Travel & Tourism drop by \$US 3.7 trillion, WTTC; <sup>3</sup> International trade is facing contraction that could reach -32%; IMF, WTO, BCG analysis; <sup>4</sup>. \$US 3 trillion excluding China. Source: World Bank, WTO, BCG analysis.